@article{2ddbae7ca9634f139771c16d60f11b4c,
title = "Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1",
abstract = "The SBG 2000-1 trial is a randomised study that investigates if dose-tailored adjuvant FEC therapy based on the individual's leukocyte nadir value can improve outcome. The study has included 1535 women with medium and high-risk breast cancer.",
keywords = "Adult, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Carcinoma, Chemotherapy, Adjuvant, Cyclophosphamide, Dose-Response Relationship, Drug, Epirubicin, Feasibility Studies, Female, Fluorouracil, Humans, Individuality, Individualized Medicine, Leukopenia, Mastectomy, Maximum Tolerated Dose, Middle Aged, Scandinavia, Severity of Illness Index, Treatment Outcome",
author = "Per Edlund and Johan Ahlgren and Karsten Bjerre and Michael Andersson and Jonas Bergh and Henning Mouridsen and Holmberg, {Stig B} and Nils-Olof Bengtsson and Jakobsen, {Erik Winther} and Susanne M{\o}ller and Henrik Lindman and Carl Blomqvist",
year = "2011",
month = apr,
doi = "10.3109/0284186X.2011.554435",
language = "English",
volume = "50",
pages = "329--37",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Medical Journals Sweden AB",
number = "3",
}